Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Corporate Transaction and Strategic Rationale
VRTX logo

Vertex Diversifies Into Endocrinology With $10 Billion Acquisition of Crinetics

VRTX8-KFiling Date: 7/7/2026
Vertex Pharmaceuticals Incorporated
Description

What this story covers

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion to establish an endocrinology pillar. The deal adds a $5 billion peak revenue opportunity through assets like PALSONIFY and atumelnant, aiming for non-GAAP operating income accretion by 2029.

Story snapshot

CompanyVertex Pharmaceuticals Incorporated
TickerVRTX
VariantStandard detailed
Duration4:23
Filing type8-K
PeriodQ3 2026
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-296710
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in